
The company announced that its board of directors would meet on Friday, November 20, 2026, to consider and approve a scheme of arrangement between the company and its equity shareholders, as reported by Business Standard. The proposal relates to the issuance of non-convertible redeemable preference shares (NCRPS) to existing equity shareholders by way of bonus. The announcement was made pursuant to Regulation 29 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the company disclosed the development in a regulatory filing dated November 16. The proposed arrangement would be considered under Section 230 and other applicable provisions of the Companies Act, 2013. According to the latest exchange notice filed on November 16, 2026, the board meeting notice is currently at the consideration stage only, with no scheme having been approved as yet. The filing was digitally signed at 3:23 pm on November 16 by Gowry A Jaishankar, DGM Legal and Company Secretary.
Alongside the board-meeting announcement, TTK Healthcare informed that its trading window would remain closed from November 16 to November 22, 2026, both days inclusive, according to Business Upturn. The restriction applies to designated persons covered under the company's code of conduct, framed in accordance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The company stated that designated persons and their immediate relatives had been informed not to trade in its shares during this period. The disclosed trading window closure from November 16 to November 22, 2026, applies specifically to Designated Persons and their immediate relatives under the SEBI regulations, which is a standard compliance measure around board meetings and is not indicative of the outcome of the deliberations. The closure prevents potential insider trading violations while sensitive price-sensitive information regarding the capital structure change is being deliberated.
TTK Healthcare shares surged 20% in intraday trade on Tuesday, hitting the upper circuit after reports of the proposed NCRPS bonus scheme, according to Business Standard. The stock opened 15% higher at ₹1,067.65 on the NSE and extended gains to hit an intraday high of ₹1,110.90. The rally helped TTK Healthcare snap its three-day losing streak, during which the stock had declined more than 3%. As of 1:20 PM, the stock was up 13.7% at ₹1,052.60, continuing to trade firmly in the green. In comparison, the benchmark Nifty 50 index was up 88 points, or 0.35%, at 25,380. Trading volume of about 1.81 lakh shares was 8.4 times the average volume of 21,420 shares, indicating strong investor interest in the proposal.
According to Business Standard, NCRPS are not the same as ordinary equity bonus shares. NCRPS are a type of preference share that carry a fixed dividend entitlement and are redeemable after a specified period, but cannot be converted into ordinary equity shares. NCRPS do not increase the shareholder's equity ownership in the company. The filing does not disclose the proposed entitlement ratio, face value, dividend rate, redemption period or other terms of the issuance. The company has not yet disclosed the precise entitlement for each shareholder or the applicable record date, if announced. Investors will need to wait for details such as the bonus ratio, number of preference shares to be issued, their financial terms and applicable record date. The issuance of preference shares as a bonus typically aims to optimize the balance sheet or provide specific returns to shareholders without diluting equity voting rights in the same manner as a traditional equity bonus issue.
TTK Healthcare Limited (NSE:TTKHLTCARE, BSE:507747), headquartered in Chennai, Tamil Nadu, operates in the pharmaceuticals and consumer healthcare sector, manufacturing and marketing a range of products including pharmaceuticals, condoms under the Kohinoor brand, and other consumer healthcare goods. The company is listed on both BSE (Scrip Code: 507747) and NSE. For the September quarter of FY27, the company's net profit grew by nearly 10% year-on-year to ₹222.9 crore, and revenue surged by 15% to ₹233.38 crore, as reported by Business Standard. The stock's current trailing P/E ratio stands at 5.30 times on a trailing EPS of ₹195.71, with a dividend yield of 0.96% and quarterly dividend of ₹2.51. The proposal, if approved, would affect the company's capital structure distinctly from a cash dividend or equity bonus, carrying different rights and terms for shareholders.